Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Information sources -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (72)	10/6/2003 9:03:39 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 269

In Vivo..... it's been around for a long time. Every report that I read (maybe 5-6 years ago??) showed insight. Good stuff. However, that MAb blurb was kinda funky, and this is just plain comedy material...... And importantly, besides Humira (which of course was developed by BASF, not one of the antibody platform-turned-product biotechs), there’s little evidence of having the ability to optimize the antibody against a target. That may be because while antibodies are a central tool in pharma genomics programs, they’ve been used as a research tool to validate the target, not the antibody itself as a drug. For example, Pfizer has been working with Abgenix’s technology for six years. But it has yet to get an antibody molecule through proof-of-concept testing, when presumably such trials would be publicly known. One reason could be that it was using antibodies as a target validation tool So, Knoll can be clearly differentiated from a biotech? And CATG isn't a "platform-turned-product" biotech? And the Abgenix/Pfizer comment is hilarious, so far off the mark that one better hope that the author didn't also write the abstracted blurb.

To: Icebrg who wrote (72)	10/8/2003 7:22:29 AM
From: Icebrg	Read Replies (1) \| Respond to of 269

BioWorld Online bioworld.com BioWorld is a for-pay service owned by Thomson. Similar to BioCentury. Their material is only available to subscribers of the service. They do however release an article per day into the public domain. These articles mostly cover some current event. Their article normally goes a little bit "deeper" than corresponding comments from more general news organizations. Today's issue for example covers the mixed results from Regeneron's IL-1 trap program. Message 19381305